Advice from the Joint Committee on Vaccination and Immunisation (JCVI) noted that it was advisable to continue the vaccination of the 50\u201364-year-old cohort because from the age of 50 years old, individuals are at a greater risk of being hospitalised as a result of COVID-19 and the result of coinfection of COVID-19 and flu is likely to be more severe. However, no decision has been made on whether the eligibility of this cohort will be made permanent.<\/p>
The Department will continue to consider the advice of the JCVI in decisions on which flu cohorts are recommended for a flu vaccine in the future. The JCVI use the National Institute for Health and Care Excellence\u2019s methodology and criteria to assess whether a vaccine programme can be considered cost effective or not.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"} } , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"} , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"} , "dateOfAnswer" : {"_value" : "2021-09-08", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1351083/answer/previousversion/18931", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"} } , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"} , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"} } , "questionFirstAnswered" : [{"_value" : "2021-09-08T15:02:32.567Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2021-08-18", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Influenza: Vaccination"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what criteria his Department will use to determine whether the temporary expansion of eligibility for flu vaccination to people aged over 50 should be made permanent.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/429", "label" : {"_value" : "Biography information for Derek Twigg"} } , "tablingMemberConstituency" : {"_value" : "Halton"} , "tablingMemberPrinted" : [{"_value" : "Derek Twigg"} ], "uin" : "40612"} , {"_about" : "http://data.parliament.uk/resources/1349570", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1349570/answer", "answerText" : {"_value" : "
The £100 million estimate set out in the Impact Statement refers to the midpoint of the potential cost of the policy; the number of staff leaving care homes and the impact on employers could be lower than this estimate. Given this uncertainty, we are continuing to monitor the uptake rate and the potential impact of the regulations on the ability of care homes to continue delivering the best quality care.<\/p>
<\/p>
The Government published operational guidance on 4 August 2021 to support providers to implement the policy. The Guidance provides information on good employment practice for care homes, including on the importance of following a fair procedure before dismissing.<\/p>
<\/p>
We are working with Skills for Care to ensure that resources such as guidance and best practice are available to support providers and local authorities with capacity and workforce planning, recruitment and well-being.<\/p>
<\/p>
To support providers with the implementation of the policy, the Advisory, Conciliation and Arbitration Service (ACAS) have published high-level advice on vaccination as a condition of deployment. ACAS are developing more detailed guidance to further support and share good practice across the sector.<\/p>
<\/p>
The full impact assessment on making COVID-19 vaccination a condition of deployment in care homes will be published as soon as possible.<\/p>
The Department has worked closely with stakeholders throughout the development of this policy and will continue to do so throughout its implementation.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"} } , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"} , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"} , "dateOfAnswer" : {"_value" : "2021-09-08", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "38355"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1349570/answer/previousversion/18938", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"} } , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"} , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"} } , "questionFirstAnswered" : [{"_value" : "2021-09-08T15:10:45.95Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2021-07-22", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, when the Government plans to publish the impact assessment on making covid-19 vaccination a condition of deployment in care homes; and what engagement is planned with the social care sector on that matter.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4510", "label" : {"_value" : "Biography information for Helen Hayes"} } , "tablingMemberConstituency" : {"_value" : "Dulwich and West Norwood"} , "tablingMemberPrinted" : [{"_value" : "Helen Hayes"} ], "uin" : "38354"} , {"_about" : "http://data.parliament.uk/resources/1349571", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1349571/answer", "answerText" : {"_value" : "
The £100 million estimate set out in the Impact Statement refers to the midpoint of the potential cost of the policy; the number of staff leaving care homes and the impact on employers could be lower than this estimate. Given this uncertainty, we are continuing to monitor the uptake rate and the potential impact of the regulations on the ability of care homes to continue delivering the best quality care.<\/p>
<\/p>
The Government published operational guidance on 4 August 2021 to support providers to implement the policy. The Guidance provides information on good employment practice for care homes, including on the importance of following a fair procedure before dismissing.<\/p>
<\/p>
We are working with Skills for Care to ensure that resources such as guidance and best practice are available to support providers and local authorities with capacity and workforce planning, recruitment and well-being.<\/p>
<\/p>
To support providers with the implementation of the policy, the Advisory, Conciliation and Arbitration Service (ACAS) have published high-level advice on vaccination as a condition of deployment. ACAS are developing more detailed guidance to further support and share good practice across the sector.<\/p>
<\/p>
The full impact assessment on making COVID-19 vaccination a condition of deployment in care homes will be published as soon as possible.<\/p>
The Department has worked closely with stakeholders throughout the development of this policy and will continue to do so throughout its implementation.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"} } , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"} , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"} , "dateOfAnswer" : {"_value" : "2021-09-08", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "38354"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1349571/answer/previousversion/18944", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"} } , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"} , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"} } , "questionFirstAnswered" : [{"_value" : "2021-09-08T15:10:45.887Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2021-07-22", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to the Statement of impact \u2013 The Health and Social Care Act 2008 (Regulated Activities) (Amendment) (Coronavirus) Regulations 2021 updated 19 July 2021 and the estimated of £100 million for making vaccination a condition of deployment in care homes, how that cost will be funded; and what (a) legal and (b) employment expertise will be made available to care home providers to implement that policy.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4510", "label" : {"_value" : "Biography information for Helen Hayes"} } , "tablingMemberConstituency" : {"_value" : "Dulwich and West Norwood"} , "tablingMemberPrinted" : [{"_value" : "Helen Hayes"} ], "uin" : "38355"} , {"_about" : "http://data.parliament.uk/resources/1348636", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1348636/answer", "answerText" : {"_value" : "
Public Health England publishes the age and sex breakdown of hospitalisations for COVID-19 for the most recent four week period on a weekly basis at the following link:<\/p>
https://www.gov.uk/government/statistics/national-flu-and-covid-19-surveillance-reports-2021-to-2022-season<\/a><\/p> The analysis is based on data from a sentinel network of acute National Health Service trusts contributing enhanced data.<\/p> PHE publishes technical briefings which provide the latest data regarding hospitalisations and deaths by variant, including the Delta variant, as well as data concerning those hospitalised with the Delta variant of COVID-19 who are vaccinated with one and both doses and unvaccinated. These data are retrospective and do not represent current hospitalisations. Data is available from 1 February 2021 at the following link:<\/p> https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201<\/a><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
}
, "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
, "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
, "dateOfAnswer" : {"_value" : "2021-09-15", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1348636/answer/previousversion/18922", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
}
, "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
, "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
}
, "questionFirstAnswered" : [{"_value" : "2021-09-15T15:51:12.987Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2021-07-20", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Coronavirus"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment the Government has made of the demographic breakdown of people who have been hospitalised with covid-19 after receiving (a) one and (b) two doses of a vaccine.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4603", "label" : {"_value" : "Biography information for Preet Kaur Gill"}
}
, "tablingMemberConstituency" : {"_value" : "Birmingham, Edgbaston"}
, "tablingMemberPrinted" : [{"_value" : "Preet Kaur Gill"}
], "uin" : "36724"}
, {"_about" : "http://data.parliament.uk/resources/1348754", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1348754/answer", "answerText" : {"_value" : " The Joint Committee on Vaccination and Immunisation (JCVI) recognises that some individuals who are severely immunosuppressed due to underlying health conditions or medical treatment may not achieve the same full immune response to the initial two dose COVID-19 vaccination course as those who are not immunosuppressed. The committee has therefore advised on 1 September that as a precautionary measure those with severe immunosuppression at or around the time of their first or second dose of COVID-19 vaccination should receive a third dose. The aim is to raise the level of immunity in these individuals closer to the level of immunity as the non-immunosuppressed achieve from two doses in Newcastle upon Tyne and other areas.<\/p> The Government has accepted this advice, which will be applied at a national level. Severe immunosuppression at the time of vaccination is defined using guidance and timings outlined at the following link:<\/p> https://www.gov.uk/government/publications/third-primary-covid-19-vaccine-dose-for-people-who-are-immunosuppressed-jcvi-advice/joint-committee-on-vaccination-and-immunisation-jcvi-advice-on-third-primary-dose-vaccination<\/a><\/p> The purpose of the separate potential booster programme is to maximise protection in those who are most vulnerable to serious COVID-19 ahead of the winter months. The JCVI published interim advice on a potential Covid-19 booster vaccination programme on 30 June 2021, which is available at the following link:<\/p> https://www.gov.uk/government/publications/jcvi-interim-advice-on-a-potential-coronavirus-covid-19-booster-vaccine-programme-for-winter-2021-to-2022/jcvi-interim-advice-potential-covid-19-booster-vaccine-programme-winter-2021-to-2022<\/a><\/p> Final decisions on the timing and scope and cohort eligibility of any COVID-19 vaccine booster\u202fprogramme will be confirmed once the JCVI has provided their final advice.<\/p> It is expected that severely immunosuppressed individuals will become eligible for a booster dose as part of any routine booster programme from around six months after their third dose, pending further advice.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
}
, "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
, "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
, "dateOfAnswer" : {"_value" : "2021-09-13", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1348754/answer/previousversion/18935", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
}
, "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
, "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
}
, "questionFirstAnswered" : [{"_value" : "2021-09-13T16:33:45.587Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2021-07-20", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, whether it is his policy to ensure that in any booster vaccine programme third doses of covid-19 vaccines are prioritised for people who are immunosuppressed in (a) Newcastle upon Tyne and (b) other areas with a number of cases.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/523", "label" : {"_value" : "Biography information for Mr Nicholas Brown"}
}
, "tablingMemberConstituency" : {"_value" : "Newcastle upon Tyne East"}
, "tablingMemberPrinted" : [{"_value" : "Mr Nicholas Brown"}
], "uin" : "36530"}
, {"_about" : "http://data.parliament.uk/resources/1348100", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1348100/answer", "answerText" : {"_value" : " Participants in all clinical trials are provided with contact details at the local site should they have any health and wellbeing concerns which may be related to the trial.<\/p> The trial\u2019s principle investigator advise the participant based on their knowledge of whether the participant received an active COVID-19 vaccine trial product or a placebo.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
}
, "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
, "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
, "dateOfAnswer" : {"_value" : "2021-07-28", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1348100/answer/previousversion/16515", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
}
, "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
, "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
}
, "questionFirstAnswered" : [{"_value" : "2021-07-28T13:36:04.413Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2021-07-19", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps his Department is taking to support the health and wellbeing needs of people who are currently participating in trials of unapproved covid-19 vaccines.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1489", "label" : {"_value" : "Biography information for Dawn Butler"}
}
, "tablingMemberConstituency" : {"_value" : "Brent Central"}
, "tablingMemberPrinted" : [{"_value" : "Dawn Butler"}
], "uin" : "35555"}
, {"_about" : "http://data.parliament.uk/resources/1348444", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1348444/answer", "answerText" : {"_value" : " As part of the commitment to ensure the safe return to international travel, the Government\u202fcontinues to engage with the European Commission and other International Partnerships on certification to ensure that travel between the United Kingdom (UK) and other nations is unhindered and supported by a common approach. The UK and European Union (EU) are aligned in the technical approach to COVID-19 status certification, with the UK supporting global consistent minimum technical standards in an interoperable and cross-border way. We are making effective use of our chair of the G7 meeting in 2021 to ensure G7 nations made a commitment that clinical trial participants will not be disadvantaged in certification processes.<\/p> Passengers from amber countries who have been fully vaccinated with vaccines authorised by the European Medicines Agency, in the U.S. Food and Drug Administration or in the Swiss vaccination programme, will be able to travel to England without quarantine, or a day eight test.<\/p> The EU has published a list of vaccines to be accepted by EU member countries which can be found at the following link:<\/p>